Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03983954
Recruitment Status : Not yet recruiting
First Posted : June 12, 2019
Last Update Posted : June 20, 2019
Sponsor:
Collaborator:
AstraZeneca Pharmaceuticals PLC
Information provided by (Responsible Party):
NeoTX Therapeutics Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : November 1, 2021
  Estimated Study Completion Date : February 28, 2022